Chloroquine structure

Chloroquine – CAS 54-05-7

€100 – €150

Chloroquine is provided by Santiago Lab. It is one of the 5 compounds recommended by WHO for the investigation of the treatment of COVID-19. You can order chloroquine individually or as a set of 5 antivirotics recommended by WHO.

Purity (LC-MS)

99 %  |  Certificate of Analysis

Package contents

Chloroquine sulfate

This compound is for research use only. We do not sell to patients.
SizeAvailabilityPriceQuantity
100 mg

In stock

 €100
1 g

In stock

 €150

Characterisation

CAS: 54-05-7

IUPAC Name: 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine

Other names: Aralen; Chingamin; Nivaquine; Chlorochin; Chloroquine

Molecular weight: 319.88 g/mol

Molecular formula: C18H26ClN3

Description

Chloroquine is a medication which is used to prevent and treat malaria in areas where malaria remains sensitive to its effects. Certain types of malaria, resistant strains, and complicated cases typically require different or additional medication. It is also occasionally used for amebiasis that is occurring outside the intestines, rheumatoid arthritis, and lupus erythematosus. Chloroquine is also being studied for the treatment of COVID-19.

Chloroquine is a member of the drug class 4-aminoquinoline and it was discovered in 1934, by chemist Hans Andersag and coworkers at the Bayer laboratories, who named it Resochin. Chloroquine has also significant antiviral effects. It increases late endosomal and lysosomal pH, resulting in the impaired release of the virus from the endosome or lysosome – the release of the virus requires a low pH. The virus is therefore unable to replicate (releasing its genetic material into the cell).

Chemicals are distributed worldwide

Buy Chloroquine now, get your order in 48 hours
  • Shipping through DHL in 48 hours
  • All compounds are safely and rigorously packed

Payment

  • We are sending the invoice the same day as the shipment
  • We are able to modify the invoice for the academic institution, so the order can be paid from grants
References

1. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020, 30 (3), 269-271.
2. Hu, T. Y.; Frieman, M.; Wolfram, J., Insights from nanomedicine into chloroquine efficacy against COVID-19. Nature Nanotechnology 2020, 1-3.
3. Gao, J.; Tian, Z.; Yang, X., Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends 2020.
4. Dong, L.; Hu, S.; Gao, J., Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics 2020, 14 (1), 58-60.
5. Cortegiani, A.; Ingoglia, G.; Ippolito, M.; Giarratano, A.; Einav, S., A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care 2020.
6. Colson, P.; Rolain, J.-M.; Lagier, J.-C.; Brouqui, P.; Raoult, D., Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020, 105932.
7. Mauthe, M.; Orhon, I.; Rocchi, C.; Zhou, X.; Luhr, M.; Hijlkema, K.-J.; Coppes, R. P.; Engedal, N.; Mari, M.; Reggiori, F., Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 2018, 14 (8), 1435-1455.
8. Marmor, M. F.; Kellner, U.; Lai, T. Y.; Melles, R. B.; Mieler, W. F., Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016, 123 (6), 1386-1394.
9. Eng, C. H.; Wang, Z.; Tkach, D.; Toral-Barza, L.; Ugwonali, S.; Liu, S.; Fitzgerald, S. L.; George, E.; Frias, E.; Cochran, N., Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proceedings of the National Academy of Sciences 2016, 113 (1), 182-187.
10. Delvecchio, R.; Higa, L. M.; Pezzuto, P.; Valadão, A. L.; Garcez, P. P.; Monteiro, F. L.; Loiola, E. C.; Dias, A. A.; Silva, F. J.; Aliota, M. T., Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses 2016, 8 (12), 322.
11. Marmor, M. F.; Kellner, U.; Lai, T. Y.; Lyons, J. S.; Mieler, W. F., Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011, 118 (2), 415-422.
12. Martin, R. E.; Marchetti, R. V.; Cowan, A. I.; Howitt, S. M.; Bröer, S.; Kirk, K., Chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Science 2009, 325 (5948), 1680-1682.
13. Wellems, T. E.; Plowe, C. V., Chloroquine-resistant malaria. The Journal of infectious diseases 2001, 184 (6), 770-776.
14. Djimdé, A.; Doumbo, O. K.; Cortese, J. F.; Kayentao, K.; Doumbo, S.; Diourté, Y.; Coulibaly, D.; Dicko, A.; Su, X.-z.; Nomura, T., A molecular marker for chloroquine-resistant falciparum malaria. New England journal of medicine 2001, 344 (4), 257-263.
15. Martin, S. K.; Oduola, A. M.; Milhous, W. K., Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 1987, 235 (4791), 899-901.
16. Krogstad, D. J.; Gluzman, I. Y.; Kyle, D. E.; Oduola, A.; Martin, S. K.; Milhous, W. K.; Schlesinger, P. H., Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 1987, 238 (4831), 1283-1285.
17. Gonasun, L. M.; Potts, A. M., In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine. Investigative Ophthalmology & Visual Science 1974, 13 (2), 107-115.

Related products: